Alzheimer's Dementia

The International Working Group has updated diagnostic guidelines for Alzheimer’s disease to include individuals with normal cognition who test positive for core biomarkers indicative of disease pathology.

Cardiovascular health of middle-aged adults was significantly associated with the risk of poor brain health later in life, according to a study published in Neurology.

Treatment with brexpiprazole 2 mg or 3 mg resulted in significant reduction in agitation over 12 weeks compared with placebo in adults with Alzheimer’s dementia, according to research published in JAMA Neurology.

New guidance from the American Academy of Neurology on early Alzheimer’s disease treatment calls for greater collaboration from patients, caregivers and clinicians as well as the embrace of new therapeutics.

The FDA has approved a supplemental new drug application for Rexulti for the treatment of agitation associated with dementia due to Alzheimer’s disease.

Non-drug interventions for people with Alzheimer’s disease and related dementias effectively lowered the risk for nursing home admission while being cost-effective, according to findings published in Alzheimer’s & Dementia.

BOSTON — Now that there are disease-modifying treatments for Alzheimer’s disease, the necessity of identifying “contemporary population-level diagnosis rates of mild cognitive impairment and dementia” is crucial, according to a presenter.

Alzamend Neuro Inc. announced initiation of a phase 1/2a clinical trial for its proprietary immunotherapy vaccineALZN002 to treat mild to moderate dementia associated with Alzheimer’s disease.

Alzheon Inc. has announced positive interim findings from an ongoing phase 2 study evaluating ALZ-801, an investigational disease-modifying treatment for Alzheimer’s disease.